Clinical trial NCT05153304: Personalized Immunotherapy in Adults With Upper Gastrointestinal Tract Cancers
Official title: A Phase I/II Study of Personalized Immunotherapy in Adults With Upper Gastrointestinal Tract Cancers
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE1
PHASE2
Conditions: Cancer of Gastrointestinal Tract
Keywords: cancer
gastrointestinal
immunotherapy
personalized cancer vaccine
nivolumab
neoantigen
vaccine
Lead sponsor: University of California, San Diego
Sponsor class: OTHER
First posted: 2021-12-10
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine if it is possible to make and safely administer a 'personalized' cancer vaccine for people diagnosed with an upper gastrointestinal tract cancer.

Detailed description: The purpose of this study is to determine if it is possible to make and safely administer a 'personalized' cancer vaccine for people diagnosed with an upper gastrointestinal tract cancer.

It is known that cancer has mutations (changes in genetic material) that are specific to an individual person and their tumor. These mutations can cause the tumor cells to produce proteins that are different from the body's normal, healthy cells. The study will use a sample of your tumor to create a vaccine against it, with the idea being that the study vaccine will "teach" the body's immune system to recognize and attack the cancer cells. The study will examine the safety of the study vaccine when given at several time points and will examine your blood for signs that the study vaccine causes the immune system to respond.

The personalized cancer vaccine will be given alone or in combination with nivolumab. Nivolumab is a drug that blocks certain proteins on cells that help to keep immune responses in check. In a healthy person, this keeps the immune system from attacking healthy cells and tissues, but cancer cells use these proteins to keep the immune system from killing cancer cells and tumors. When these proteins are blocked, the check on the immune system is removed and immune cells may be able to recognize and kill cancer cells.

This personalized cancer vaccine is considered experimental because it is not approved by the US Food \& Drug Administration (FDA) as a treatment for cancer.

The combination of nivolumab and the personalized cancer vaccine is experimental and is not FDA approved.

Eligibility criteria: Inclusion Criteria:

* Histologically or cytologically documented gastroespohageal or gastric adenocarcinoma.
* Measurable disease as defined by RECIST 1.1
* Adequate organ function
* Women of child-bearing potential and men with partners of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence)

Exclusion Criteria:

* Currently receiving or has received another anti-cancer therapy within 4 weeks prior to first dose of vaccine study treatment.
* Currently receiving or has received PD1/PDL1 inhibitor immunotherapy within 4 weeks prior to first dose of study treatment.
* Received an investigational agent within 28 days prior to the first dose of study drug.
* Untreated brain metastases; individuals with treated and stable metastases are eligible. Eligible subjects should have recovered from the acute effects of radiation therapy or surgery prior to study entry, have discontinued corticosteroid treatment for brain metastases for at least 4 weeks and are neurologically stable for 8 weeks (confirmed by MRI) prior to administration of experimental therapy
* Has known history of Human Immunodeficiency Virus (HIV).
* Received a diagnosis of hepatitis B or hepatitis C for which there is no clear evidence of natural immunity, immunity subsequent to vaccination, or successful eradication of the virus following antiviral therapy (individuals who are hepatitis C antibody positive may be enrolled if negative viral load confirmed).
* History of autoimmune disease including: inflammatory bowel disease (including ulcerative colitis and Crohn's Disease), rheumatoid arthritis, systemic progressive sclerosis (scleroderma), systemic lupus erythematosus, autoimmune vasculitis (e.g. Wegener's granulomatosis); central nervous system or motor neuropathy considered of autoimmune origin (e.g. Guillain-Barré syndrome, myasthenia gravis, multiple sclerosis). Individuals with vitiligo, Sjogren's Syndrome, interstitial cystitis, Graves' or Hashimoto's Disease, celiac disease, DM1, or hypothyroidism stable on hormone replacement will be allowed with Study Medical Monitor's approval.
* Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis.
* History of receiving a solid organ transplant or allogeneic bone marrow transplant.
* Major surgical procedure within 28 days prior to the first dose of study drug.
* If female, pregnant or breastfeeding.

Primary outcomes:
measure: Quantitative frequency of TCR
timeFrame: 1 year
measure: Treatment-related Adverse Events
timeFrame: 1 year
Secondary outcomes:
measure: Progression-free survival (PFS)
timeFrame: 1 year
measure: Overall Survival
timeFrame: 1 year
measure: Overall Response
timeFrame: 1 year
measure: Duration of response
timeFrame: 1 year
Other outcomes:
Locations:
city: La Jolla
country: United States
facility: University of California, San Diego
state: California
Study officials:
affiliation: University of California, San Diego
name: Ezra Cohen, MD
role: PRINCIPAL_INVESTIGATOR
References: